<?xml version="1.0" encoding="UTF-8" ?>
			<?xml-stylesheet href="/rss/rss2html.xsl" type="text/xsl" media="screen"?>
			<rss version="2.0" xmlns:alacra="http://www.alacra.com" xmlns:ccbn="http://www.alacra.com/ccbn" xmlns:sdc="http://www.alacra.com/sdc" ><channel><title>Richter Gedeon Nyrt. RSS Research Feed - Subscribe Today - AlacraStore.com</title>
<description>Richter Gedeon Nyrt.</description>
<link>http://www.alacrastore.com/company-snapshot/Richter_Gedeon_Nyrt-1048457</link>
<lastBuildDate>16 Mar 2010 03:29:30 EST</lastBuildDate>
<alacra:xlsid>1048457</alacra:xlsid>
<alacra:company>Richter Gedeon Nyrt.</alacra:company>
<language>en</language>
<generator>AlacraStore RSS Builder 1.0</generator>
<ttl>30</ttl>
<alacra:host>www.alacrastore.com</alacra:host>
<item><title>Aberdeen Asset Management PLC acquires a minority stake in Richter Gedeon Nyrt</title><description>HUNGARY - Aberdeen Asset Management PLC of the UK acquired a ##.##% stake in Richter Gedeon Nyrt, a Budapest-based manufacturer of pharmaceuticals.</description><pubDate>13 Nov 2009 11:06:57 EST</pubDate><sdc:company_cusip xmlns:sdc="http://www.alacra.com/sdc">G00434</sdc:company_cusip><sdc:target_company_cusip xmlns:sdc="http://www.alacra.com/sdc">76549A</sdc:target_company_cusip><sdc:company_cusip_up xmlns:sdc="http://www.alacra.com/sdc">G00434</sdc:company_cusip_up><sdc:target_company_cusip_up xmlns:sdc="http://www.alacra.com/sdc">76549A</sdc:target_company_cusip_up><sdc:company xmlns:sdc="http://www.alacra.com/sdc">Aberdeen Asset Management PLC</sdc:company><sdc:target_company xmlns:sdc="http://www.alacra.com/sdc">Richter Gedeon Nyrt</sdc:target_company><sdc:company_up xmlns:sdc="http://www.alacra.com/sdc">Aberdeen Asset Management PLC</sdc:company_up><sdc:target_company_up xmlns:sdc="http://www.alacra.com/sdc">Richter Gedeon Nyrt</sdc:target_company_up><link>http://www.alacrastore.com/storecontent/Thomson_M%26A/Aberdeen_Asset_Management_PLC_acquires_a_minority_stake_in_Richter_Gedeon_Nyrt-2126917040</link><guid isPermaLink="false">sdc/2126917040</guid><sdc:deal xmlns:sdc="http://www.alacra.com/sdc"><sdc:deal_no>2126917040</sdc:deal_no><sdc:_copyright><sdc:value>Copyright Â© 2009, Thomson Financial, All Rights Reserved</sdc:value></sdc:_copyright><sdc:a_EXCHANGE><sdc:value>London</sdc:value></sdc:a_EXCHANGE><sdc:a_MAINDUSTRY><sdc:value>Investment &amp; Commodity Firms,Dealers,Exchanges</sdc:value></sdc:a_MAINDUSTRY><sdc:a_NATION><sdc:value>United Kingdom</sdc:value></sdc:a_NATION><sdc:a_SICDESC><sdc:value>Investment advice</sdc:value></sdc:a_SICDESC><sdc:a_SICPI><sdc:value>6282</sdc:value></sdc:a_SICPI><sdc:a_STATE><sdc:value>FF</sdc:value></sdc:a_STATE><sdc:a_STATELONG><sdc:value>Foreign</sdc:value></sdc:a_STATELONG><sdc:a_STATUS><sdc:value>Public</sdc:value></sdc:a_STATUS><sdc:a_TICKER><sdc:value>ADN</sdc:value></sdc:a_TICKER><sdc:asic_SIC><sdc:value sdc:p="0">6282:Investment advice</sdc:value><sdc:value sdc:p="1">6722:Management investment offices, open-end</sdc:value><sdc:value sdc:p="2">6726:Investment offices, nec</sdc:value><sdc:value sdc:p="3">6799:Investors, nec</sdc:value></sdc:asic_SIC><sdc:aupsic_SIC><sdc:value sdc:p="0">6282:Investment advice</sdc:value><sdc:value sdc:p="1">6722:Management investment offices, open-end</sdc:value><sdc:value sdc:p="2">6726:Investment offices, nec</sdc:value><sdc:value sdc:p="3">6799:Investors, nec</sdc:value></sdc:aupsic_SIC><sdc:b_EXCHANGE><sdc:value>Budapest</sdc:value></sdc:b_EXCHANGE><sdc:b_MAINDUSTRY><sdc:value>Drugs</sdc:value></sdc:b_MAINDUSTRY><sdc:b_NATION><sdc:value>Hungary</sdc:value></sdc:b_NATION><sdc:b_SICDESC><sdc:value>Pharmaceutical preparations</sdc:value></sdc:b_SICDESC><sdc:b_SICPI><sdc:value>2834</sdc:value></sdc:b_SICPI><sdc:b_STATE><sdc:value>FF</sdc:value></sdc:b_STATE><sdc:b_STATELONG><sdc:value>Foreign</sdc:value></sdc:b_STATELONG><sdc:b_STATUS><sdc:value>Public</sdc:value></sdc:b_STATUS><sdc:b_TICKER><sdc:value>RICHTE</sdc:value></sdc:b_TICKER><sdc:c_ACIDGEN><sdc:value>125374002</sdc:value></sdc:c_ACIDGEN><sdc:c2up_BUSS><sdc:value>Pvd asset mgmt svcs</sdc:value></sdc:c2up_BUSS><sdc:c3up_BUSS><sdc:value>Mnfr pharm prod</sdc:value></sdc:c3up_BUSS><sdc:co_DESCR><sdc:value>Unspecified</sdc:value></sdc:co_DESCR><sdc:cs_DESCR><sdc:value>Stock</sdc:value></sdc:cs_DESCR><sdc:d_TCIDGEN><sdc:value>153150002</sdc:value></sdc:d_TCIDGEN><sdc:date_lastupdate><sdc:value>Nov 13 2009</sdc:value></sdc:date_lastupdate><sdc:finbltm_BV><sdc:value>105.59500</sdc:value></sdc:finbltm_BV><sdc:finbltm_CASH><sdc:value>583.72000</sdc:value></sdc:finbltm_CASH><sdc:finbltm_CASHFLOW><sdc:value>330.20700</sdc:value></sdc:finbltm_CASHFLOW><sdc:finbltm_CASHFLOW1><sdc:value>298.42400</sdc:value></sdc:finbltm_CASHFLOW1><sdc:finbltm_CASHFLOW2><sdc:value>305.22500</sdc:value></sdc:finbltm_CASHFLOW2><sdc:finbltm_CASHFLOW3><sdc:value>367.66300</sdc:value></sdc:finbltm_CASHFLOW3><sdc:finbltm_CASHFLOW4><sdc:value>301.11900</sdc:value></sdc:finbltm_CASHFLOW4><sdc:finbltm_CASHFLOW5><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW5><sdc:finbltm_COMEQ><sdc:value>1963.16800</sdc:value></sdc:finbltm_COMEQ><sdc:finbltm_DEBTRAT><sdc:value>0.12900</sdc:value></sdc:finbltm_DEBTRAT><sdc:finbltm_DSER2><sdc:value>0.01700</sdc:value></sdc:finbltm_DSER2><sdc:finbltm_EBIT><sdc:value>218.59500</sdc:value></sdc:finbltm_EBIT><sdc:finbltm_EPS><sdc:value>15.08300</sdc:value></sdc:finbltm_EPS><sdc:finbltm_NI><sdc:value>280.67900</sdc:value></sdc:finbltm_NI><sdc:finbltm_PTINC><sdc:value>293.98100</sdc:value></sdc:finbltm_PTINC><sdc:finbltm_SALES><sdc:value>1424.85800</sdc:value></sdc:finbltm_SALES><sdc:finbltm_STDEBT><sdc:value>27.93800</sdc:value></sdc:finbltm_STDEBT><sdc:finbltm_TASS><sdc:value>2270.52100</sdc:value></sdc:finbltm_TASS><sdc:fiscal_ACURR_CODE><sdc:value>STG</sdc:value></sdc:fiscal_ACURR_CODE><sdc:fiscal_ADATEFIN><sdc:value>30 Sep 08</sdc:value></sdc:fiscal_ADATEFIN><sdc:fiscal_ADCR><sdc:value>0.00000</sdc:value></sdc:fiscal_ADCR><sdc:fiscal_ANI><sdc:value>62.80100</sdc:value></sdc:fiscal_ANI><sdc:fiscal_APFDCR><sdc:value>0.00000</sdc:value></sdc:fiscal_APFDCR><sdc:fiscal_ASALES><sdc:value>766.97200</sdc:value></sdc:fiscal_ASALES><sdc:fiscal_ATASS><sdc:value>4185.26200</sdc:value></sdc:fiscal_ATASS><sdc:fiscal_CURRENCYLONG><sdc:value>British Pound</sdc:value></sdc:fiscal_CURRENCYLONG><sdc:fiscal_DATEFIN><sdc:value>30 Sep 09</sdc:value></sdc:fiscal_DATEFIN><sdc:fiscal_FISCAL><sdc:value>31 Dec 08</sdc:value></sdc:fiscal_FISCAL><sdc:fiscal_FISCAL1><sdc:value>31 Dec 07</sdc:value></sdc:fiscal_FISCAL1><sdc:fiscal_FISCAL2><sdc:value>31 Dec 06</sdc:value></sdc:fiscal_FISCAL2><sdc:fiscal_FISCAL3><sdc:value>31 Dec 05</sdc:value></sdc:fiscal_FISCAL3><sdc:fiscal_FISCAL4><sdc:value>31 Dec 04</sdc:value></sdc:fiscal_FISCAL4><sdc:fiscal_RATE><sdc:value>0.00500</sdc:value></sdc:fiscal_RATE><sdc:g_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value><sdc:value sdc:p="6">7.00000</sdc:value><sdc:value sdc:p="7">8.00000</sdc:value><sdc:value sdc:p="8">9.00000</sdc:value><sdc:value sdc:p="9">10.00000</sdc:value><sdc:value sdc:p="10">11.00000</sdc:value><sdc:value sdc:p="11">12.00000</sdc:value><sdc:value sdc:p="12">13.00000</sdc:value></sdc:g_SEQ><sdc:g_TEST><sdc:value sdc:p="0">Aberdeen Asset Management PLC,</sdc:value><sdc:value sdc:p="1">based in Aberdeen, UK,</sdc:value><sdc:value sdc:p="2">provides asset management</sdc:value><sdc:value sdc:p="3">services such as investment</sdc:value><sdc:value sdc:p="4">management and property asset</sdc:value><sdc:value sdc:p="5">management services to</sdc:value><sdc:value sdc:p="6">institutions and private</sdc:value><sdc:value sdc:p="7">individuals. It has 18</sdc:value><sdc:value sdc:p="8">investments trusts and global</sdc:value><sdc:value sdc:p="9">offices in the US, Asia</sdc:value><sdc:value sdc:p="10">Pacific, Europe, and the UK.</sdc:value><sdc:value sdc:p="11">The company was founded in</sdc:value><sdc:value sdc:p="12">1983.</sdc:value></sdc:g_TEST><sdc:g_business><sdc:value sdc:p="0">Aberdeen Asset Management PLC, based in Aberdeen, UK,</sdc:value><sdc:value sdc:p="1">provides asset management services such as investment</sdc:value><sdc:value sdc:p="2">management and property asset management services to</sdc:value><sdc:value sdc:p="3">institutions and private individuals. It has 18 investments</sdc:value><sdc:value sdc:p="4">trusts and global offices in the US, Asia Pacific, Europe,</sdc:value><sdc:value sdc:p="5">and the UK. The company was founded in 1983.</sdc:value></sdc:g_business><sdc:g_business1><sdc:value>Aberdeen Asset Management PLC, based in Aberdeen, UK, provides asset management services such as investment management and property asset management services to institutions and private individuals. It has 18 investments trusts and global offices in the US, Asia Pacific, Europe, and the UK. The company was founded in 1983.</sdc:value></sdc:g_business1><sdc:h_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value><sdc:value sdc:p="6">7.00000</sdc:value><sdc:value sdc:p="7">8.00000</sdc:value><sdc:value sdc:p="8">9.00000</sdc:value><sdc:value sdc:p="9">10.00000</sdc:value><sdc:value sdc:p="10">11.00000</sdc:value><sdc:value sdc:p="11">12.00000</sdc:value><sdc:value sdc:p="12">13.00000</sdc:value><sdc:value sdc:p="13">14.00000</sdc:value><sdc:value sdc:p="14">15.00000</sdc:value><sdc:value sdc:p="15">16.00000</sdc:value><sdc:value sdc:p="16">17.00000</sdc:value><sdc:value sdc:p="17">18.00000</sdc:value></sdc:h_SEQ><sdc:h_TEST><sdc:value sdc:p="0">Richter Gedeon Nyrt, located</sdc:value><sdc:value sdc:p="1">in Budapest, Hungary,</sdc:value><sdc:value sdc:p="2">manufactures pharmaceutical</sdc:value><sdc:value sdc:p="3">products. The company is also</sdc:value><sdc:value sdc:p="4">engaged in the development of</sdc:value><sdc:value sdc:p="5">generic drugs and chemical</sdc:value><sdc:value sdc:p="6">processes. Its original</sdc:value><sdc:value sdc:p="7">pharmaceutical research</sdc:value><sdc:value sdc:p="8">activities focuses on the</sdc:value><sdc:value sdc:p="9">identification of active</sdc:value><sdc:value sdc:p="10">ingredients that are effective</sdc:value><sdc:value sdc:p="11">in the treatment of diseases</sdc:value><sdc:value sdc:p="12">of the central nervous system,</sdc:value><sdc:value sdc:p="13">primarily molecules that are</sdc:value><sdc:value sdc:p="14">suitable for the alleviation</sdc:value><sdc:value sdc:p="15">of chronic pain, schizophrenia</sdc:value><sdc:value sdc:p="16">and anxiety. The company was</sdc:value><sdc:value sdc:p="17">founded in 1901.</sdc:value></sdc:h_TEST><sdc:h_business><sdc:value sdc:p="0">Richter Gedeon Nyrt, located in Budapest, Hungary,</sdc:value><sdc:value sdc:p="1">manufactures pharmaceutical products. The company is also</sdc:value><sdc:value sdc:p="2">engaged in the development of generic drugs and chemical</sdc:value><sdc:value sdc:p="3">processes. Its original pharmaceutical research activities</sdc:value><sdc:value sdc:p="4">focuses on the identification of active ingredients that are</sdc:value><sdc:value sdc:p="5">effective in the treatment of diseases of the central</sdc:value><sdc:value sdc:p="6">nervous system, primarily molecules that are suitable for</sdc:value><sdc:value sdc:p="7">the alleviation of chronic pain, schizophrenia and anxiety.</sdc:value><sdc:value sdc:p="8">The company was founded in 1901.</sdc:value></sdc:h_business><sdc:h_business1><sdc:value>Richter Gedeon Nyrt, located in Budapest, Hungary, manufactures pharmaceutical products. The company is also engaged in the development of generic drugs and chemical processes. Its original pharmaceutical research activities focuses on the identification of active ingredients that are effective in the treatment of diseases of the central nervous system, primarily molecules that are suitable for the alleviation of chronic pain, schizophrenia and anxiety. The company was founded in 1901.</sdc:value></sdc:h_business1><sdc:i_AFEEPCT><sdc:value>0.00000</sdc:value></sdc:i_AFEEPCT><sdc:i_AFEETOT><sdc:value>0.00000</sdc:value></sdc:i_AFEETOT><sdc:i_ATERMFEE><sdc:value>0.00000</sdc:value></sdc:i_ATERMFEE><sdc:i_COMOUT><sdc:value>18.64000</sdc:value></sdc:i_COMOUT><sdc:i_CROSS1><sdc:value>Y</sdc:value></sdc:i_CROSS1><sdc:i_DATEANN><sdc:value>11 Nov 09</sdc:value></sdc:i_DATEANN><sdc:i_DATEANN2><sdc:value>Wed, 11 Nov 2009 00:00:00 EST</sdc:value></sdc:i_DATEANN2><sdc:i_DATEANNS><sdc:value>Date Announced: 11/11/2009</sdc:value></sdc:i_DATEANNS><sdc:i_DATEEFF><sdc:value>11 Nov 09</sdc:value></sdc:i_DATEEFF><sdc:i_DATEEFFS><sdc:value>Date Effective: 11/11/2009</sdc:value></sdc:i_DATEEFFS><sdc:i_DATEUNCON><sdc:value>11 Nov 09</sdc:value></sdc:i_DATEUNCON><sdc:i_DESCR><sdc:value>Acq. Part. Int.</sdc:value></sdc:i_DESCR><sdc:i_DESCR1><sdc:value>Friendly</sdc:value></sdc:i_DESCR1><sdc:i_FEEPCT><sdc:value>0.00000</sdc:value></sdc:i_FEEPCT><sdc:i_FEETOT><sdc:value>0.00000</sdc:value></sdc:i_FEETOT><sdc:i_HOSTAFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTAFEETOT><sdc:i_HOSTENTVAL><sdc:value>0.00000</sdc:value></sdc:i_HOSTENTVAL><sdc:i_HOSTFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTFEETOT><sdc:i_HOSTPR><sdc:value>0.00000</sdc:value></sdc:i_HOSTPR><sdc:i_HOSTPRLABEL><sdc:value>Price/Share</sdc:value></sdc:i_HOSTPRLABEL><sdc:i_HOSTTFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTTFEETOT><sdc:i_HOSTVALUE><sdc:value>0</sdc:value></sdc:i_HOSTVALUE><sdc:i_HOSTVALUE1><sdc:value>0.00000</sdc:value></sdc:i_HOSTVALUE1><sdc:i_HOST_EQVAL><sdc:value>0.00000</sdc:value></sdc:i_HOST_EQVAL><sdc:i_HOST_RANKVAL><sdc:value>0</sdc:value></sdc:i_HOST_RANKVAL><sdc:i_HOST_RANKVAL1><sdc:value>0.00000</sdc:value></sdc:i_HOST_RANKVAL1><sdc:i_PCTACQ><sdc:value>10.05000</sdc:value></sdc:i_PCTACQ><sdc:i_PCTOWN><sdc:value>10.05000</sdc:value></sdc:i_PCTOWN><sdc:i_PR><sdc:value>0.00000</sdc:value></sdc:i_PR><sdc:i_PR_INITIAL><sdc:value>0.00000</sdc:value></sdc:i_PR_INITIAL><sdc:i_RANKVAL><sdc:value>0.00000</sdc:value></sdc:i_RANKVAL><sdc:i_RANK_HOSTRANKVAL><sdc:value>0</sdc:value></sdc:i_RANK_HOSTRANKVAL><sdc:i_RATE><sdc:value>0.00000</sdc:value></sdc:i_RATE><sdc:i_STATUS_MMC><sdc:value>N</sdc:value></sdc:i_STATUS_MMC><sdc:i_STGVAL><sdc:value>0.00000</sdc:value></sdc:i_STGVAL><sdc:i_TERMFEE><sdc:value>0.00000</sdc:value></sdc:i_TERMFEE><sdc:i_TFEEPCT><sdc:value>0.00000</sdc:value></sdc:i_TFEEPCT><sdc:i_TFEETOT><sdc:value>0.00000</sdc:value></sdc:i_TFEETOT><sdc:i_TTERMFEE><sdc:value>0.00000</sdc:value></sdc:i_TTERMFEE><sdc:i_VALLIA><sdc:value>0.00000</sdc:value></sdc:i_VALLIA><sdc:i_VALNOLIA><sdc:value>0.00000</sdc:value></sdc:i_VALNOLIA><sdc:i_VALUE><sdc:value>0.00000</sdc:value></sdc:i_VALUE><sdc:j_EQVALCF><sdc:value>0.00000</sdc:value></sdc:j_EQVALCF><sdc:j_EVCF><sdc:value>0.00000</sdc:value></sdc:j_EVCF><sdc:j_EVEBIT><sdc:value>0.00000</sdc:value></sdc:j_EVEBIT><sdc:j_EVNI><sdc:value>0.00000</sdc:value></sdc:j_EVNI><sdc:j_EVSALES><sdc:value>0.00000</sdc:value></sdc:j_EVSALES><sdc:j_MPE><sdc:value>0.00000</sdc:value></sdc:j_MPE><sdc:j_MPRICEBOOK><sdc:value>0.00000</sdc:value></sdc:j_MPRICEBOOK><sdc:j_PHELD><sdc:value>0.00000</sdc:value></sdc:j_PHELD><sdc:j_PSOUGHT><sdc:value>10.05000</sdc:value></sdc:j_PSOUGHT><sdc:j_RANKVALCF><sdc:value>0.00000</sdc:value></sdc:j_RANKVALCF><sdc:j_RANKVALEB><sdc:value>0.00000</sdc:value></sdc:j_RANKVALEB><sdc:j_RANKVALNA><sdc:value>0.00000</sdc:value></sdc:j_RANKVALNA><sdc:j_RANKVALNI><sdc:value>0.00000</sdc:value></sdc:j_RANKVALNI><sdc:j_RANKVALSALES><sdc:value>0.00000</sdc:value></sdc:j_RANKVALSALES><sdc:j_VALEB><sdc:value>0.00000</sdc:value></sdc:j_VALEB><sdc:j_VALNI><sdc:value>0.00000</sdc:value></sdc:j_VALNI><sdc:j_VALSALES><sdc:value>0.00000</sdc:value></sdc:j_VALSALES><sdc:m_AMV><sdc:value>0.00000</sdc:value></sdc:m_AMV><sdc:m_C1DAY><sdc:value>232.33200</sdc:value></sdc:m_C1DAY><sdc:m_C1WK><sdc:value>224.26600</sdc:value></sdc:m_C1WK><sdc:m_C4WK><sdc:value>219.55900</sdc:value></sdc:m_C4WK><sdc:m_CF3YGR><sdc:value>-9.90700</sdc:value></sdc:m_CF3YGR><sdc:m_CF5YGR><sdc:value>0.00000</sdc:value></sdc:m_CF5YGR><sdc:m_DCR><sdc:value>0.00300</sdc:value></sdc:m_DCR><sdc:m_ENTVAL><sdc:value>0.00000</sdc:value></sdc:m_ENTVAL><sdc:m_EPS3YGR><sdc:value>-10.05900</sdc:value></sdc:m_EPS3YGR><sdc:m_EPS5YGR><sdc:value>0.97800</sdc:value></sdc:m_EPS5YGR><sdc:m_LTD><sdc:value>5.18400</sdc:value></sdc:m_LTD><sdc:m_MV><sdc:value>4066.35500</sdc:value></sdc:m_MV><sdc:m_NETASS><sdc:value>1977.03000</sdc:value></sdc:m_NETASS><sdc:m_NETASS3YGR><sdc:value>7.43900</sdc:value></sdc:m_NETASS3YGR><sdc:m_NETASS5YGR><sdc:value>12.20300</sdc:value></sdc:m_NETASS5YGR><sdc:m_NI3YGR><sdc:value>-10.13600</sdc:value></sdc:m_NI3YGR><sdc:m_NI5YGR><sdc:value>0.96800</sdc:value></sdc:m_NI5YGR><sdc:n_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value></sdc:n_SEQ><sdc:n_SYNOPSIS><sdc:value sdc:p="0">HUNGARY - Aberdeen Asset</sdc:value><sdc:value sdc:p="1">Management PLC of the UK</sdc:value><sdc:value sdc:p="2">acquired a 10.05% stake in</sdc:value><sdc:value sdc:p="3">Richter Gedeon Nyrt, a</sdc:value><sdc:value sdc:p="4">Budapest-based manufacturer</sdc:value><sdc:value sdc:p="5">of pharmaceuticals.</sdc:value></sdc:n_SYNOPSIS><sdc:n_synopsis2><sdc:value>HUNGARY - Aberdeen Asset Management PLC of the UK acquired a 10.05% stake in Richter Gedeon Nyrt, a Budapest-based manufacturer of pharmaceuticals.</sdc:value></sdc:n_synopsis2><sdc:n_synopsis3><sdc:value sdc:p="0">HUNGARY - Aberdeen Asset Management PLC of the UK acquired a 10.05% stake in Richter</sdc:value><sdc:value sdc:p="1">Gedeon Nyrt, a Budapest-based manufacturer of pharmaceuticals.</sdc:value></sdc:n_synopsis3><sdc:n_synopsis4><sdc:value>HUNGARY - Aberdeen Asset Management PLC of the UK acquired a 10.05% stake in Richter Gedeon Nyrt, a Budapest-based manufacturer of pharmaceuticals.</sdc:value></sdc:n_synopsis4><sdc:n_synopsis5><sdc:value sdc:p="0">HUNGARY - Aberdeen Asset Management PLC of the UK acquired a 10.05% stake in Richter Gedeon Nyrt, a Budapest-based manufacturer of</sdc:value><sdc:value sdc:p="1">pharmaceuticals.</sdc:value></sdc:n_synopsis5><sdc:q_DESCR><sdc:value>Completed</sdc:value></sdc:q_DESCR><sdc:q_HOSTANETASS><sdc:value>743.30300</sdc:value></sdc:q_HOSTANETASS><sdc:q_HOSTANILTM><sdc:value>35.21600</sdc:value></sdc:q_HOSTANILTM><sdc:q_HOSTASALESLTM><sdc:value>430.08600</sdc:value></sdc:q_HOSTASALESLTM><sdc:q_HOSTATASS><sdc:value>2346.92000</sdc:value></sdc:q_HOSTATASS><sdc:q_HOSTBOOKVALUE><sdc:value>19393.10800</sdc:value></sdc:q_HOSTBOOKVALUE><sdc:q_HOSTCASHFLOW><sdc:value>60644.00000</sdc:value></sdc:q_HOSTCASHFLOW><sdc:q_HOSTCASHFLOW1><sdc:value>54807.00000</sdc:value></sdc:q_HOSTCASHFLOW1><sdc:q_HOSTCASHFLOW2><sdc:value>56056.00000</sdc:value></sdc:q_HOSTCASHFLOW2><sdc:q_HOSTCASHFLOW3><sdc:value>67523.00000</sdc:value></sdc:q_HOSTCASHFLOW3><sdc:q_HOSTCASHFLOW4><sdc:value>55302.00000</sdc:value></sdc:q_HOSTCASHFLOW4><sdc:q_HOSTCASHFLOW5><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW5><sdc:q_HOSTCOMMONEQUITY><sdc:value>360545.00000</sdc:value></sdc:q_HOSTCOMMONEQUITY><sdc:q_HOSTEBITLTM><sdc:value>40146.00000</sdc:value></sdc:q_HOSTEBITLTM><sdc:q_HOSTEPS1><sdc:value>2227.00000</sdc:value></sdc:q_HOSTEPS1><sdc:q_HOSTEPS2><sdc:value>1792.00000</sdc:value></sdc:q_HOSTEPS2><sdc:q_HOSTEPS3><sdc:value>2753.00000</sdc:value></sdc:q_HOSTEPS3><sdc:q_HOSTEPS4><sdc:value>2436.00000</sdc:value></sdc:q_HOSTEPS4><sdc:q_HOSTEPS5><sdc:value>2142.00000</sdc:value></sdc:q_HOSTEPS5><sdc:q_HOSTEPSLTM><sdc:value>2770.00000</sdc:value></sdc:q_HOSTEPSLTM><sdc:q_HOSTNETASS><sdc:value>363091.00000</sdc:value></sdc:q_HOSTNETASS><sdc:q_HOSTNETASS1><sdc:value>339286.00000</sdc:value></sdc:q_HOSTNETASS1><sdc:q_HOSTNETASS2><sdc:value>314381.00000</sdc:value></sdc:q_HOSTNETASS2><sdc:q_HOSTNETASS3><sdc:value>293928.00000</sdc:value></sdc:q_HOSTNETASS3><sdc:q_HOSTNETASS4><sdc:value>253026.00000</sdc:value></sdc:q_HOSTNETASS4><sdc:q_HOSTNETASS5><sdc:value>214063.00000</sdc:value></sdc:q_HOSTNETASS5><sdc:q_HOSTNI1><sdc:value>41410.00000</sdc:value></sdc:q_HOSTNI1><sdc:q_HOSTNI2><sdc:value>33336.00000</sdc:value></sdc:q_HOSTNI2><sdc:q_HOSTNI3><sdc:value>51278.00000</sdc:value></sdc:q_HOSTNI3><sdc:q_HOSTNI4><sdc:value>45313.00000</sdc:value></sdc:q_HOSTNI4><sdc:q_HOSTNI5><sdc:value>39845.00000</sdc:value></sdc:q_HOSTNI5><sdc:q_HOSTNILTM><sdc:value>51548.00000</sdc:value></sdc:q_HOSTNILTM><sdc:q_HOSTPTINC1><sdc:value>43453.00000</sdc:value></sdc:q_HOSTPTINC1><sdc:q_HOSTPTINC2><sdc:value>35780.00000</sdc:value></sdc:q_HOSTPTINC2><sdc:q_HOSTPTINC3><sdc:value>52113.00000</sdc:value></sdc:q_HOSTPTINC3><sdc:q_HOSTPTINC4><sdc:value>46186.00000</sdc:value></sdc:q_HOSTPTINC4><sdc:q_HOSTPTINC5><sdc:value>39936.00000</sdc:value></sdc:q_HOSTPTINC5><sdc:q_HOSTPTINCLTM><sdc:value>53991.00000</sdc:value></sdc:q_HOSTPTINCLTM><sdc:q_HOSTSALES1><sdc:value>236101.00000</sdc:value></sdc:q_HOSTSALES1><sdc:q_HOSTSALES2><sdc:value>223624.00000</sdc:value></sdc:q_HOSTSALES2><sdc:q_HOSTSALES3><sdc:value>208620.00000</sdc:value></sdc:q_HOSTSALES3><sdc:q_HOSTSALES4><sdc:value>171720.00000</sdc:value></sdc:q_HOSTSALES4><sdc:q_HOSTSALES5><sdc:value>148755.00000</sdc:value></sdc:q_HOSTSALES5><sdc:q_HOSTSALESLTM><sdc:value>261682.00000</sdc:value></sdc:q_HOSTSALESLTM><sdc:q_HOSTTASS><sdc:value>416992.00000</sdc:value></sdc:q_HOSTTASS><sdc:q_HOSTTASS1><sdc:value>383085.00000</sdc:value></sdc:q_HOSTTASS1><sdc:q_HOSTTASS2><sdc:value>347174.00000</sdc:value></sdc:q_HOSTTASS2><sdc:q_HOSTTASS3><sdc:value>324718.00000</sdc:value></sdc:q_HOSTTASS3><sdc:q_HOSTTASS4><sdc:value>276636.00000</sdc:value></sdc:q_HOSTTASS4><sdc:q_HOSTTASS5><sdc:value>234178.00000</sdc:value></sdc:q_HOSTTASS5><sdc:q_STATUS><sdc:value>Status:Completed</sdc:value></sdc:q_STATUS><sdc:r_CURR_CODE><sdc:value>HF</sdc:value></sdc:r_CURR_CODE><sdc:r_PE><sdc:value>-999.00000</sdc:value></sdc:r_PE><sdc:r_PE_PRINT><sdc:value>np</sdc:value></sdc:r_PE_PRINT><sdc:r_PFTMARG><sdc:value>0.20600</sdc:value></sdc:r_PFTMARG><sdc:r_PRICEBOOK><sdc:value>-999.00000</sdc:value></sdc:r_PRICEBOOK><sdc:r_PRICEBOOK_PRINT><sdc:value>np</sdc:value></sdc:r_PRICEBOOK_PRINT><sdc:r_PTINC3YGR><sdc:value>-8.68600</sdc:value></sdc:r_PTINC3YGR><sdc:r_PTINC5YGR><sdc:value>2.13200</sdc:value></sdc:r_PTINC5YGR><sdc:r_ROE><sdc:value>14.29700</sdc:value></sdc:r_ROE><sdc:r_SALES3YGR><sdc:value>6.38300</sdc:value></sdc:r_SALES3YGR><sdc:r_SALES5YGR><sdc:value>12.24200</sdc:value></sdc:r_SALES5YGR><sdc:r_SE><sdc:value>1963.16800</sdc:value></sdc:r_SE><sdc:r_TASS3YGR><sdc:value>8.61600</sdc:value></sdc:r_TASS3YGR><sdc:r_TASS5YGR><sdc:value>13.09300</sdc:value></sdc:r_TASS5YGR><sdc:r_TTCFMULT><sdc:value>0.00000</sdc:value></sdc:r_TTCFMULT><sdc:r_TTEBITMULT><sdc:value>0.00000</sdc:value></sdc:r_TTEBITMULT><sdc:r_VALNA><sdc:value>0.00000</sdc:value></sdc:r_VALNA><sdc:sic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value></sdc:sic_SIC><sdc:upa_UPACIDGEN><sdc:value>125374002</sdc:value></sdc:upa_UPACIDGEN><sdc:upa1_EXCHANGE><sdc:value>London</sdc:value></sdc:upa1_EXCHANGE><sdc:upa1_NATION><sdc:value>United Kingdom</sdc:value></sdc:upa1_NATION><sdc:upa1_SICP><sdc:value>6282</sdc:value></sdc:upa1_SICP><sdc:upa1_STATE><sdc:value>Foreign</sdc:value></sdc:upa1_STATE><sdc:upa1_STATUS><sdc:value>Public</sdc:value></sdc:upa1_STATUS><sdc:upa1_TICKER><sdc:value>ADN</sdc:value></sdc:upa1_TICKER><sdc:upsic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value></sdc:upsic_SIC><sdc:upt_UPTCIDGEN><sdc:value>153150002</sdc:value></sdc:upt_UPTCIDGEN><sdc:upt1_EXCHANGE><sdc:value>Budapest</sdc:value></sdc:upt1_EXCHANGE><sdc:upt1_NATION><sdc:value>Hungary</sdc:value></sdc:upt1_NATION><sdc:upt1_SICP><sdc:value>2834</sdc:value></sdc:upt1_SICP><sdc:upt1_STATE><sdc:value>Foreign</sdc:value></sdc:upt1_STATE><sdc:upt1_STATUS><sdc:value>Public</sdc:value></sdc:upt1_STATUS><sdc:upt1_TICKER><sdc:value>RICHTE</sdc:value></sdc:upt1_TICKER><sdc:x_RANK1_VALUE><sdc:value>0.00000</sdc:value></sdc:x_RANK1_VALUE><sdc:x_RANK_HOSTRANKVAL><sdc:value>0.00000</sdc:value></sdc:x_RANK_HOSTRANKVAL><sdc:x_RANK_RANKVAL><sdc:value>0.00000</sdc:value></sdc:x_RANK_RANKVAL><sdc:x_rank_rankstgval><sdc:value>0.00000</sdc:value></sdc:x_rank_rankstgval></sdc:deal><category>Deal Information</category><alacra:ip>TF Mergers &amp; Acquisitions</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T2542055</link><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2542055</ccbn:docid><guid isPermaLink="false">ccbn/T2542055</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><pubDate>10 Nov 2009 04:06:00 EST</pubDate><ccbn:eventid xmlns:ccbn="http://www.alacra.com/ccbn">2542055</ccbn:eventid><ccbn:headline xmlns:ccbn="http://www.alacra.com/ccbn">Final Transcript of RICHTER earnings conference call or presentation, 10-Nov-09 4:00pm CET</ccbn:headline><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Gedeon Richter Ltd.</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Gedeon Richter Ltd. Q3 2009 Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">RICHTER</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">4:00pm CET</ccbn:time><title>Gedeon Richter Ltd. Q3 2009 Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><description>...Erik Bogsch Gedeon Richter Ltd. - Managing Director Katalin Ordog Gedeon Richter Ltd. - IR Gabor Gulacsi Gedeon Richter Ltd. - Deputy Managing Director...

</description><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T2364146</link><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2364146</ccbn:docid><guid isPermaLink="false">ccbn/T2364146</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><pubDate>04 Aug 2009 09:07:00 EST</pubDate><ccbn:eventid xmlns:ccbn="http://www.alacra.com/ccbn">2364146</ccbn:eventid><ccbn:headline xmlns:ccbn="http://www.alacra.com/ccbn">Final Transcript of RICHTER earnings conference call or presentation, 4-Aug-09 4:00pm CET</ccbn:headline><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Gedeon Richter Ltd.</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Gedeon Richter Ltd. Q2 2009 Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">RICHTER</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">4:00pm CET</ccbn:time><title>Gedeon Richter Ltd. Q2 2009 Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><description>...Erik Bogsch Gedeon Richter Ltd. - Managing Director Katalin Ordog Gedeon Richter Ltd. - Head of IR Gabor Gulacsi Gedeon Richter Ltd. - Deputy Managing Director C O N F E R E N C E C A L L P A R T I C I P A N T S...

</description><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><title>Barclays Global Investors UK acquires a minority stake in Richter Gedeon Nyrt</title><description>HUNGARY - Barclays Global Investors UK Holdings Ltd of the UK, a unit of Barclays PLC, acquired a #.##% stake, or #.### mil ordinary shares, in Richter Gedeon Nyrt, a Budapest-based manufacturer of pharmaceutical products, in a privately negotiated transaction.</description><pubDate>25 Apr 2009 07:57:28 EST</pubDate><sdc:company_cusip xmlns:sdc="http://www.alacra.com/sdc">06782L</sdc:company_cusip><sdc:target_company_cusip xmlns:sdc="http://www.alacra.com/sdc">76549A</sdc:target_company_cusip><sdc:company_cusip_up xmlns:sdc="http://www.alacra.com/sdc">06738E</sdc:company_cusip_up><sdc:target_company_cusip_up xmlns:sdc="http://www.alacra.com/sdc">76549A</sdc:target_company_cusip_up><sdc:company xmlns:sdc="http://www.alacra.com/sdc">Barclays Global Investors UK Holdings Ltd</sdc:company><sdc:target_company xmlns:sdc="http://www.alacra.com/sdc">Richter Gedeon Nyrt</sdc:target_company><sdc:company_up xmlns:sdc="http://www.alacra.com/sdc">Barclays PLC</sdc:company_up><sdc:target_company_up xmlns:sdc="http://www.alacra.com/sdc">Richter Gedeon Nyrt</sdc:target_company_up><link>http://www.alacrastore.com/storecontent/Thomson_M%26A/Barclays_Global_Investors_UK_acquires_a_minority_stake_in_Richter_Gedeon_Nyrt-2067940040</link><guid isPermaLink="false">sdc/2067940040</guid><sdc:deal xmlns:sdc="http://www.alacra.com/sdc"><sdc:deal_no>2067940040</sdc:deal_no><sdc:_copyright><sdc:value>Copyright Â© 2009, Thomson Financial, All Rights Reserved</sdc:value></sdc:_copyright><sdc:a_MAINDUSTRY><sdc:value>Holding Companies, Except Banks</sdc:value></sdc:a_MAINDUSTRY><sdc:a_NATION><sdc:value>United Kingdom</sdc:value></sdc:a_NATION><sdc:a_SICDESC><sdc:value>Offices of holding companies, nec</sdc:value></sdc:a_SICDESC><sdc:a_SICPI><sdc:value>6719</sdc:value></sdc:a_SICPI><sdc:a_STATE><sdc:value>FF</sdc:value></sdc:a_STATE><sdc:a_STATELONG><sdc:value>Foreign</sdc:value></sdc:a_STATELONG><sdc:a_STATUS><sdc:value>Subsidiary</sdc:value></sdc:a_STATUS><sdc:asic_SIC><sdc:value sdc:p="0">6719:Offices of holding companies, nec</sdc:value><sdc:value sdc:p="1">6799:Investors, nec</sdc:value></sdc:asic_SIC><sdc:aupsic_SIC><sdc:value sdc:p="0">6000:Banks</sdc:value><sdc:value sdc:p="1">6282:Investment advice</sdc:value><sdc:value sdc:p="2">6289:Security and commodity services, nec</sdc:value><sdc:value sdc:p="3">6719:Offices of holding companies, nec</sdc:value></sdc:aupsic_SIC><sdc:b_EXCHANGE><sdc:value>Budapest</sdc:value></sdc:b_EXCHANGE><sdc:b_MAINDUSTRY><sdc:value>Drugs</sdc:value></sdc:b_MAINDUSTRY><sdc:b_NATION><sdc:value>Hungary</sdc:value></sdc:b_NATION><sdc:b_SICDESC><sdc:value>Pharmaceutical preparations</sdc:value></sdc:b_SICDESC><sdc:b_SICPI><sdc:value>2834</sdc:value></sdc:b_SICPI><sdc:b_STATE><sdc:value>FF</sdc:value></sdc:b_STATE><sdc:b_STATELONG><sdc:value>Foreign</sdc:value></sdc:b_STATELONG><sdc:b_STATUS><sdc:value>Public</sdc:value></sdc:b_STATUS><sdc:b_TICKER><sdc:value>RICHTE</sdc:value></sdc:b_TICKER><sdc:c_ACIDGEN><sdc:value>1078072001</sdc:value></sdc:c_ACIDGEN><sdc:c2up_BUSS><sdc:value>Pvd bkg,finl svcs</sdc:value></sdc:c2up_BUSS><sdc:c3up_BUSS><sdc:value>Mnfr pharm prod</sdc:value></sdc:c3up_BUSS><sdc:co_DESCR><sdc:value>Unspecified</sdc:value></sdc:co_DESCR><sdc:cs_DESCR><sdc:value>Ordinary Share</sdc:value></sdc:cs_DESCR><sdc:d_TCIDGEN><sdc:value>153150002</sdc:value></sdc:d_TCIDGEN><sdc:date_lastupdate><sdc:value>Apr 25 2009</sdc:value></sdc:date_lastupdate><sdc:finbltm_BV><sdc:value>0.00000</sdc:value></sdc:finbltm_BV><sdc:finbltm_CASH><sdc:value>0.00000</sdc:value></sdc:finbltm_CASH><sdc:finbltm_CASHFLOW><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW><sdc:finbltm_CASHFLOW1><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW1><sdc:finbltm_CASHFLOW2><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW2><sdc:finbltm_CASHFLOW3><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW3><sdc:finbltm_CASHFLOW4><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW4><sdc:finbltm_CASHFLOW5><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW5><sdc:finbltm_COMEQ><sdc:value>0.00000</sdc:value></sdc:finbltm_COMEQ><sdc:finbltm_DEBTRAT><sdc:value>0.00000</sdc:value></sdc:finbltm_DEBTRAT><sdc:finbltm_DSER2><sdc:value>0.00000</sdc:value></sdc:finbltm_DSER2><sdc:finbltm_EBIT><sdc:value>0.00000</sdc:value></sdc:finbltm_EBIT><sdc:finbltm_EPS><sdc:value>0.00000</sdc:value></sdc:finbltm_EPS><sdc:finbltm_NI><sdc:value>0.00000</sdc:value></sdc:finbltm_NI><sdc:finbltm_PTINC><sdc:value>0.00000</sdc:value></sdc:finbltm_PTINC><sdc:finbltm_SALES><sdc:value>0.00000</sdc:value></sdc:finbltm_SALES><sdc:finbltm_STDEBT><sdc:value>0.00000</sdc:value></sdc:finbltm_STDEBT><sdc:finbltm_TASS><sdc:value>0.00000</sdc:value></sdc:finbltm_TASS><sdc:fiscal_ADCR><sdc:value>0.00000</sdc:value></sdc:fiscal_ADCR><sdc:fiscal_ANI><sdc:value>0.00000</sdc:value></sdc:fiscal_ANI><sdc:fiscal_APFDCR><sdc:value>0.00000</sdc:value></sdc:fiscal_APFDCR><sdc:fiscal_ASALES><sdc:value>0.00000</sdc:value></sdc:fiscal_ASALES><sdc:fiscal_ATASS><sdc:value>0.00000</sdc:value></sdc:fiscal_ATASS><sdc:fiscal_RATE><sdc:value>0.00000</sdc:value></sdc:fiscal_RATE><sdc:g_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value></sdc:g_SEQ><sdc:g_TEST><sdc:value sdc:p="0">Barclays Global Investors UK</sdc:value><sdc:value sdc:p="1">Holdings Ltd, based in London,</sdc:value><sdc:value sdc:p="2">UK, is an investment holding</sdc:value><sdc:value sdc:p="3">company.</sdc:value></sdc:g_TEST><sdc:g_business><sdc:value sdc:p="0">Barclays Global Investors UK Holdings Ltd, based in London,</sdc:value><sdc:value sdc:p="1">UK, is an investment holding company.</sdc:value></sdc:g_business><sdc:g_business1><sdc:value>Barclays Global Investors UK Holdings Ltd, based in London, UK, is an investment holding company.</sdc:value></sdc:g_business1><sdc:h_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value><sdc:value sdc:p="6">7.00000</sdc:value><sdc:value sdc:p="7">8.00000</sdc:value><sdc:value sdc:p="8">9.00000</sdc:value><sdc:value sdc:p="9">10.00000</sdc:value><sdc:value sdc:p="10">11.00000</sdc:value><sdc:value sdc:p="11">12.00000</sdc:value><sdc:value sdc:p="12">13.00000</sdc:value><sdc:value sdc:p="13">14.00000</sdc:value><sdc:value sdc:p="14">15.00000</sdc:value><sdc:value sdc:p="15">16.00000</sdc:value><sdc:value sdc:p="16">17.00000</sdc:value><sdc:value sdc:p="17">18.00000</sdc:value></sdc:h_SEQ><sdc:h_TEST><sdc:value sdc:p="0">Richter Gedeon Nyrt, located</sdc:value><sdc:value sdc:p="1">in Budapest, Hungary,</sdc:value><sdc:value sdc:p="2">manufactures pharmaceutical</sdc:value><sdc:value sdc:p="3">products. The company is also</sdc:value><sdc:value sdc:p="4">engaged in the development of</sdc:value><sdc:value sdc:p="5">generic drugs and chemical</sdc:value><sdc:value sdc:p="6">processes. Its original</sdc:value><sdc:value sdc:p="7">pharmaceutical research</sdc:value><sdc:value sdc:p="8">activities focuses on the</sdc:value><sdc:value sdc:p="9">identification of active</sdc:value><sdc:value sdc:p="10">ingredients that are effective</sdc:value><sdc:value sdc:p="11">in the treatment of diseases</sdc:value><sdc:value sdc:p="12">of the central nervous system,</sdc:value><sdc:value sdc:p="13">primarily molecules that are</sdc:value><sdc:value sdc:p="14">suitable for the alleviation</sdc:value><sdc:value sdc:p="15">of chronic pain, schizophrenia</sdc:value><sdc:value sdc:p="16">and anxiety. The company was</sdc:value><sdc:value sdc:p="17">founded in 1901.</sdc:value></sdc:h_TEST><sdc:h_business><sdc:value sdc:p="0">Richter Gedeon Nyrt, located in Budapest, Hungary,</sdc:value><sdc:value sdc:p="1">manufactures pharmaceutical products. The company is also</sdc:value><sdc:value sdc:p="2">engaged in the development of generic drugs and chemical</sdc:value><sdc:value sdc:p="3">processes. Its original pharmaceutical research activities</sdc:value><sdc:value sdc:p="4">focuses on the identification of active ingredients that are</sdc:value><sdc:value sdc:p="5">effective in the treatment of diseases of the central</sdc:value><sdc:value sdc:p="6">nervous system, primarily molecules that are suitable for</sdc:value><sdc:value sdc:p="7">the alleviation of chronic pain, schizophrenia and anxiety.</sdc:value><sdc:value sdc:p="8">The company was founded in 1901.</sdc:value></sdc:h_business><sdc:h_business1><sdc:value>Richter Gedeon Nyrt, located in Budapest, Hungary, manufactures pharmaceutical products. The company is also engaged in the development of generic drugs and chemical processes. Its original pharmaceutical research activities focuses on the identification of active ingredients that are effective in the treatment of diseases of the central nervous system, primarily molecules that are suitable for the alleviation of chronic pain, schizophrenia and anxiety. The company was founded in 1901.</sdc:value></sdc:h_business1><sdc:i_AFEEPCT><sdc:value>0.00000</sdc:value></sdc:i_AFEEPCT><sdc:i_AFEETOT><sdc:value>0.00000</sdc:value></sdc:i_AFEETOT><sdc:i_ATERMFEE><sdc:value>0.00000</sdc:value></sdc:i_ATERMFEE><sdc:i_COMOUT><sdc:value>18.64000</sdc:value></sdc:i_COMOUT><sdc:i_CROSS1><sdc:value>Y</sdc:value></sdc:i_CROSS1><sdc:i_DATEANN><sdc:value>22 Apr 09</sdc:value></sdc:i_DATEANN><sdc:i_DATEANN2><sdc:value>Wed, 22 Apr 2009 00:00:00 EST</sdc:value></sdc:i_DATEANN2><sdc:i_DATEANNS><sdc:value>Date Announced: 04/22/2009</sdc:value></sdc:i_DATEANNS><sdc:i_DATEEFF><sdc:value>22 Apr 09</sdc:value></sdc:i_DATEEFF><sdc:i_DATEEFFS><sdc:value>Date Effective: 04/22/2009</sdc:value></sdc:i_DATEEFFS><sdc:i_DATEUNCON><sdc:value>22 Apr 09</sdc:value></sdc:i_DATEUNCON><sdc:i_DESCR><sdc:value>Acq. Part. Int.</sdc:value></sdc:i_DESCR><sdc:i_DESCR1><sdc:value>Friendly</sdc:value></sdc:i_DESCR1><sdc:i_FEEPCT><sdc:value>0.00000</sdc:value></sdc:i_FEEPCT><sdc:i_FEETOT><sdc:value>0.00000</sdc:value></sdc:i_FEETOT><sdc:i_HOSTAFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTAFEETOT><sdc:i_HOSTENTVAL><sdc:value>0.00000</sdc:value></sdc:i_HOSTENTVAL><sdc:i_HOSTFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTFEETOT><sdc:i_HOSTPR><sdc:value>0.00000</sdc:value></sdc:i_HOSTPR><sdc:i_HOSTPRLABEL><sdc:value>Price/Share</sdc:value></sdc:i_HOSTPRLABEL><sdc:i_HOSTTFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTTFEETOT><sdc:i_HOSTVALUE><sdc:value>0</sdc:value></sdc:i_HOSTVALUE><sdc:i_HOSTVALUE1><sdc:value>0.00000</sdc:value></sdc:i_HOSTVALUE1><sdc:i_HOST_EQVAL><sdc:value>0.00000</sdc:value></sdc:i_HOST_EQVAL><sdc:i_HOST_RANKVAL><sdc:value>0</sdc:value></sdc:i_HOST_RANKVAL><sdc:i_HOST_RANKVAL1><sdc:value>0.00000</sdc:value></sdc:i_HOST_RANKVAL1><sdc:i_PCTACQ><sdc:value>5.09000</sdc:value></sdc:i_PCTACQ><sdc:i_PCTOWN><sdc:value>5.09000</sdc:value></sdc:i_PCTOWN><sdc:i_PR><sdc:value>0.00000</sdc:value></sdc:i_PR><sdc:i_PR_INITIAL><sdc:value>0.00000</sdc:value></sdc:i_PR_INITIAL><sdc:i_RANKVAL><sdc:value>0.00000</sdc:value></sdc:i_RANKVAL><sdc:i_RANK_HOSTRANKVAL><sdc:value>0</sdc:value></sdc:i_RANK_HOSTRANKVAL><sdc:i_RATE><sdc:value>0.00000</sdc:value></sdc:i_RATE><sdc:i_STATUS_MMC><sdc:value>N</sdc:value></sdc:i_STATUS_MMC><sdc:i_STGVAL><sdc:value>0.00000</sdc:value></sdc:i_STGVAL><sdc:i_TERMFEE><sdc:value>0.00000</sdc:value></sdc:i_TERMFEE><sdc:i_TFEEPCT><sdc:value>0.00000</sdc:value></sdc:i_TFEEPCT><sdc:i_TFEETOT><sdc:value>0.00000</sdc:value></sdc:i_TFEETOT><sdc:i_TTERMFEE><sdc:value>0.00000</sdc:value></sdc:i_TTERMFEE><sdc:i_VALLIA><sdc:value>0.00000</sdc:value></sdc:i_VALLIA><sdc:i_VALNOLIA><sdc:value>0.00000</sdc:value></sdc:i_VALNOLIA><sdc:i_VALUE><sdc:value>0.00000</sdc:value></sdc:i_VALUE><sdc:j_EQVALCF><sdc:value>0.00000</sdc:value></sdc:j_EQVALCF><sdc:j_EVCF><sdc:value>0.00000</sdc:value></sdc:j_EVCF><sdc:j_EVEBIT><sdc:value>0.00000</sdc:value></sdc:j_EVEBIT><sdc:j_EVNI><sdc:value>0.00000</sdc:value></sdc:j_EVNI><sdc:j_EVSALES><sdc:value>0.00000</sdc:value></sdc:j_EVSALES><sdc:j_MPE><sdc:value>0.00000</sdc:value></sdc:j_MPE><sdc:j_MPRICEBOOK><sdc:value>0.00000</sdc:value></sdc:j_MPRICEBOOK><sdc:j_PHELD><sdc:value>0.00000</sdc:value></sdc:j_PHELD><sdc:j_PSOUGHT><sdc:value>5.09000</sdc:value></sdc:j_PSOUGHT><sdc:j_RANKVALCF><sdc:value>0.00000</sdc:value></sdc:j_RANKVALCF><sdc:j_RANKVALEB><sdc:value>0.00000</sdc:value></sdc:j_RANKVALEB><sdc:j_RANKVALNA><sdc:value>0.00000</sdc:value></sdc:j_RANKVALNA><sdc:j_RANKVALNI><sdc:value>0.00000</sdc:value></sdc:j_RANKVALNI><sdc:j_RANKVALSALES><sdc:value>0.00000</sdc:value></sdc:j_RANKVALSALES><sdc:j_VALEB><sdc:value>0.00000</sdc:value></sdc:j_VALEB><sdc:j_VALNI><sdc:value>0.00000</sdc:value></sdc:j_VALNI><sdc:j_VALSALES><sdc:value>0.00000</sdc:value></sdc:j_VALSALES><sdc:m_AMV><sdc:value>0.00000</sdc:value></sdc:m_AMV><sdc:m_C1DAY><sdc:value>121.99600</sdc:value></sdc:m_C1DAY><sdc:m_C1WK><sdc:value>120.67400</sdc:value></sdc:m_C1WK><sdc:m_C4WK><sdc:value>119.59500</sdc:value></sdc:m_C4WK><sdc:m_CF3YGR><sdc:value>0.00000</sdc:value></sdc:m_CF3YGR><sdc:m_CF5YGR><sdc:value>0.00000</sdc:value></sdc:m_CF5YGR><sdc:m_DCR><sdc:value>0.00000</sdc:value></sdc:m_DCR><sdc:m_ENTVAL><sdc:value>0.00000</sdc:value></sdc:m_ENTVAL><sdc:m_EPS3YGR><sdc:value>0.00000</sdc:value></sdc:m_EPS3YGR><sdc:m_EPS5YGR><sdc:value>0.00000</sdc:value></sdc:m_EPS5YGR><sdc:m_LTD><sdc:value>0.00000</sdc:value></sdc:m_LTD><sdc:m_MV><sdc:value>2161.27700</sdc:value></sdc:m_MV><sdc:m_NETASS><sdc:value>0.00000</sdc:value></sdc:m_NETASS><sdc:m_NETASS3YGR><sdc:value>0.00000</sdc:value></sdc:m_NETASS3YGR><sdc:m_NETASS5YGR><sdc:value>0.00000</sdc:value></sdc:m_NETASS5YGR><sdc:m_NI3YGR><sdc:value>0.00000</sdc:value></sdc:m_NI3YGR><sdc:m_NI5YGR><sdc:value>0.00000</sdc:value></sdc:m_NI5YGR><sdc:n_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value><sdc:value sdc:p="6">7.00000</sdc:value><sdc:value sdc:p="7">8.00000</sdc:value><sdc:value sdc:p="8">9.00000</sdc:value><sdc:value sdc:p="9">10.00000</sdc:value></sdc:n_SEQ><sdc:n_SYNOPSIS><sdc:value sdc:p="0">HUNGARY - Barclays Global</sdc:value><sdc:value sdc:p="1">Investors UK Holdings Ltd of</sdc:value><sdc:value sdc:p="2">the UK, a unit of Barclays</sdc:value><sdc:value sdc:p="3">PLC, acquired a 5.09% stake,</sdc:value><sdc:value sdc:p="4">or 0.949 mil ordinary shares,</sdc:value><sdc:value sdc:p="5">in Richter Gedeon Nyrt, a</sdc:value><sdc:value sdc:p="6">Budapest-based manufacturer</sdc:value><sdc:value sdc:p="7">of pharmaceutical products,</sdc:value><sdc:value sdc:p="8">in a privately negotiated</sdc:value><sdc:value sdc:p="9">transaction.</sdc:value></sdc:n_SYNOPSIS><sdc:n_synopsis2><sdc:value>HUNGARY - Barclays Global Investors UK Holdings Ltd of the UK, a unit of Barclays PLC, acquired a 5.09% stake, or 0.949 mil ordinary shares, in Richter Gedeon Nyrt, a Budapest-based manufacturer of pharmaceutical products, in a privately negotiated transaction.</sdc:value></sdc:n_synopsis2><sdc:n_synopsis3><sdc:value sdc:p="0">HUNGARY - Barclays Global Investors UK Holdings Ltd of the UK, a unit of Barclays PLC,</sdc:value><sdc:value sdc:p="1">acquired a 5.09% stake, or 0.949 mil ordinary shares, in Richter Gedeon Nyrt, a</sdc:value><sdc:value sdc:p="2">Budapest-based manufacturer of pharmaceutical products, in a privately negotiated</sdc:value><sdc:value sdc:p="3">transaction.</sdc:value></sdc:n_synopsis3><sdc:n_synopsis4><sdc:value sdc:p="0">HUNGARY - Barclays Global Investors UK Holdings Ltd of the UK, a unit of Barclays PLC, acquired a 5.09% stake, or 0.949 mil ordinary shares, in Richter Gedeon Nyrt, a Budapest-based manufacturer of</sdc:value><sdc:value sdc:p="1">pharmaceutical products, in a privately negotiated transaction.</sdc:value></sdc:n_synopsis4><sdc:n_synopsis5><sdc:value sdc:p="0">HUNGARY - Barclays Global Investors UK Holdings Ltd of the UK, a unit of Barclays PLC, acquired a 5.09% stake, or 0.949 mil ordinary</sdc:value><sdc:value sdc:p="1">shares, in Richter Gedeon Nyrt, a Budapest-based manufacturer of pharmaceutical products, in a privately negotiated transaction.</sdc:value></sdc:n_synopsis5><sdc:q_DESCR><sdc:value>Completed</sdc:value></sdc:q_DESCR><sdc:q_HOSTANETASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTANETASS><sdc:q_HOSTANILTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTANILTM><sdc:q_HOSTASALESLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTASALESLTM><sdc:q_HOSTATASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTATASS><sdc:q_HOSTBOOKVALUE><sdc:value>0.00000</sdc:value></sdc:q_HOSTBOOKVALUE><sdc:q_HOSTCASHFLOW><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW><sdc:q_HOSTCASHFLOW1><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW1><sdc:q_HOSTCASHFLOW2><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW2><sdc:q_HOSTCASHFLOW3><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW3><sdc:q_HOSTCASHFLOW4><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW4><sdc:q_HOSTCASHFLOW5><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW5><sdc:q_HOSTCOMMONEQUITY><sdc:value>0.00000</sdc:value></sdc:q_HOSTCOMMONEQUITY><sdc:q_HOSTEBITLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTEBITLTM><sdc:q_HOSTEPS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS1><sdc:q_HOSTEPS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS2><sdc:q_HOSTEPS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS3><sdc:q_HOSTEPS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS4><sdc:q_HOSTEPS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS5><sdc:q_HOSTEPSLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPSLTM><sdc:q_HOSTNETASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS><sdc:q_HOSTNETASS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS1><sdc:q_HOSTNETASS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS2><sdc:q_HOSTNETASS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS3><sdc:q_HOSTNETASS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS4><sdc:q_HOSTNETASS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS5><sdc:q_HOSTNI1><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI1><sdc:q_HOSTNI2><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI2><sdc:q_HOSTNI3><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI3><sdc:q_HOSTNI4><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI4><sdc:q_HOSTNI5><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI5><sdc:q_HOSTNILTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTNILTM><sdc:q_HOSTPTINC1><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC1><sdc:q_HOSTPTINC2><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC2><sdc:q_HOSTPTINC3><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC3><sdc:q_HOSTPTINC4><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC4><sdc:q_HOSTPTINC5><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC5><sdc:q_HOSTPTINCLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINCLTM><sdc:q_HOSTSALES1><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES1><sdc:q_HOSTSALES2><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES2><sdc:q_HOSTSALES3><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES3><sdc:q_HOSTSALES4><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES4><sdc:q_HOSTSALES5><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES5><sdc:q_HOSTSALESLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALESLTM><sdc:q_HOSTTASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS><sdc:q_HOSTTASS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS1><sdc:q_HOSTTASS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS2><sdc:q_HOSTTASS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS3><sdc:q_HOSTTASS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS4><sdc:q_HOSTTASS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS5><sdc:q_STATUS><sdc:value>Status:Completed</sdc:value></sdc:q_STATUS><sdc:r_PE><sdc:value>-999.00000</sdc:value></sdc:r_PE><sdc:r_PE_PRINT><sdc:value>np</sdc:value></sdc:r_PE_PRINT><sdc:r_PFTMARG><sdc:value>0.00000</sdc:value></sdc:r_PFTMARG><sdc:r_PRICEBOOK><sdc:value>-999.00000</sdc:value></sdc:r_PRICEBOOK><sdc:r_PRICEBOOK_PRINT><sdc:value>np</sdc:value></sdc:r_PRICEBOOK_PRINT><sdc:r_PTINC3YGR><sdc:value>0.00000</sdc:value></sdc:r_PTINC3YGR><sdc:r_PTINC5YGR><sdc:value>0.00000</sdc:value></sdc:r_PTINC5YGR><sdc:r_ROE><sdc:value>0.00000</sdc:value></sdc:r_ROE><sdc:r_SALES3YGR><sdc:value>0.00000</sdc:value></sdc:r_SALES3YGR><sdc:r_SALES5YGR><sdc:value>0.00000</sdc:value></sdc:r_SALES5YGR><sdc:r_SE><sdc:value>0.00000</sdc:value></sdc:r_SE><sdc:r_TASS3YGR><sdc:value>0.00000</sdc:value></sdc:r_TASS3YGR><sdc:r_TASS5YGR><sdc:value>0.00000</sdc:value></sdc:r_TASS5YGR><sdc:r_TTCFMULT><sdc:value>0.00000</sdc:value></sdc:r_TTCFMULT><sdc:r_TTEBITMULT><sdc:value>0.00000</sdc:value></sdc:r_TTEBITMULT><sdc:r_VALNA><sdc:value>0.00000</sdc:value></sdc:r_VALNA><sdc:sic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value></sdc:sic_SIC><sdc:upa_UPACIDGEN><sdc:value>652001</sdc:value></sdc:upa_UPACIDGEN><sdc:upa1_EXCHANGE><sdc:value>London</sdc:value></sdc:upa1_EXCHANGE><sdc:upa1_NATION><sdc:value>United Kingdom</sdc:value></sdc:upa1_NATION><sdc:upa1_SICP><sdc:value>6000</sdc:value></sdc:upa1_SICP><sdc:upa1_STATE><sdc:value>Foreign</sdc:value></sdc:upa1_STATE><sdc:upa1_STATUS><sdc:value>Public</sdc:value></sdc:upa1_STATUS><sdc:upa1_TICKER><sdc:value>BARC</sdc:value></sdc:upa1_TICKER><sdc:upsic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value></sdc:upsic_SIC><sdc:upt_UPTCIDGEN><sdc:value>153150002</sdc:value></sdc:upt_UPTCIDGEN><sdc:upt1_EXCHANGE><sdc:value>Budapest</sdc:value></sdc:upt1_EXCHANGE><sdc:upt1_NATION><sdc:value>Hungary</sdc:value></sdc:upt1_NATION><sdc:upt1_SICP><sdc:value>2834</sdc:value></sdc:upt1_SICP><sdc:upt1_STATE><sdc:value>Foreign</sdc:value></sdc:upt1_STATE><sdc:upt1_STATUS><sdc:value>Public</sdc:value></sdc:upt1_STATUS><sdc:upt1_TICKER><sdc:value>RICHTE</sdc:value></sdc:upt1_TICKER><sdc:x_RANK1_VALUE><sdc:value>0.00000</sdc:value></sdc:x_RANK1_VALUE><sdc:x_RANK_HOSTRANKVAL><sdc:value>0.00000</sdc:value></sdc:x_RANK_HOSTRANKVAL><sdc:x_RANK_RANKVAL><sdc:value>0.00000</sdc:value></sdc:x_RANK_RANKVAL><sdc:x_rank_rankstgval><sdc:value>0.00000</sdc:value></sdc:x_rank_rankstgval></sdc:deal><category>Deal Information</category><alacra:ip>TF Mergers &amp; Acquisitions</alacra:ip></item></channel></rss>